[DOI] [PMC free article] [PubMed] [Google Scholar] 77.Ottolini M., Hong K., Cope E.L., Daneva Z., Johnstone S.R., Isakson B., Sonkusare S.K
Image courtesy of Jamesbrianbounds , CC BY-SA 4.0 , via Wikimedia Commons References [1] Huang, Q., Liao, C., Ge, F., Ao, J
Get personalized protocols for cagrilintide monotherapy or CagriSema combination, titration schedules based on GI tolerance, side effect management strategies, and maintenance dosing after weight loss
Changes in BMI and Fat Mass GLP-1 RAs (e.g., liraglutide, semaglutide, exenatide) consistently reduce BMI and fat mass in T2D patients, primarily through appetite suppression and delayed gastric emptying [12, 13, 31]